China: Johnson & Johnson monopoly ruling hits several milestones for antitrust law
Johnson & Johnson became the first Fortune 500 company to be ruled a monopoly by a Chinese court, say reports. The decision reflects the nation’s strengthening position against price-fixing, say analysts. The verdict, delivered Thursday, ordered the US-based pharmaceutical giant to pay about $86,500 to an ex-dealer on which J&J imposed a price floor, said the Shanghai High People’s Court. The company forced minimum retail prices on its former China-based dealer Rainbow Medical. Chief judge Ding Wenlian said the medical instrument market in the nation has “faced a lack of competition. The ruling marks the first antitrust ruling in favor of the plaintiff, and the first vertical monopoly lawsuit in China since the establishment of the nation’s Anti-monopoly Law, which went into effect five years ago.
Featured News
White House Prepares Overhaul of U.S. Cyber Rules
Dec 16, 2025 by
CPI
DirecTV Wins Second Chance in Antitrust Case Against Nexstar
Dec 16, 2025 by
CPI
Democrats Call for Tough Review of Nexstar-Tegna Merger
Dec 16, 2025 by
CPI
US FTC and States Expand Suit Accusing Uber of Deceptive Subscription Practices
Dec 16, 2025 by
CPI
US Hits Pause on Implementing UK Trade Deal Amid Disagreement on Digital Regs
Dec 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi